Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Combination of capecitabine and ludartin inhibits colon cancer growth in mice

Li-xia Huang¹, Min-yu Zhong², Dan Dan², Xiao-mei Yang², Hui Qiu², Pei-zhong Guo²

¹School of Medicine, Jianghan University, WuHan, HuBei Province 430056 2Department of Oncology, Wuhan Integrated Integrated TCM and Western Medicine Hospital, Wuhan HuBei 430022; ²School of Medicine, Jianghan University, WuHan, HuBei Province 430056, China.

For correspondence:- Pei-zhong Guo Email: hlxgw2011@163.com Tel:+862785379530

Accepted: 6 October 2017 Published: 30 November 2017

Citation: Huang L, Zhong M, Dan D, Yang X, Qiu H, Guo P. Combination of capecitabine and ludartin inhibits colon cancer growth in mice. Trop J Pharm Res 2017; 16(11):2623-2628 doi: 10.4314/tjpr.v16i11.8

© 2017 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To investigate the efficacy of capecitabine and ludartin in the treatment of colon cancer in mice.

Methods: Mice model of colon cancer was used in this study. Quantitative real-time polymerase chain reaction (Qrt-PCR) was used to quantify the expression of vascular endothelial growth factor (VEGF) mRNA. Micro-vessel density was assessed using immunohistochemical analysis.

Results: When administered separately, capecitabine and ludartin treatments significantly suppressed tumor growth in the mice model of colon cancer for 4 weeks, compared to control group. Co-administration of capecitabine and ludartin significantly inhibited tumor growth for 6 weeks (p < 0.05). Symptoms of colon cancer such as weight loss, skin discoloration and leukopenia were observed in untreated control group. However, these symptoms were completely absent in the group treated with combination of capecitabine and ludartin. The combined treatment also prevented colon cancer-induced increase in white blood cell (WBC) count, and increased median survival time of colon cancer mice from 38 to 55 days. expression of VEGF in combination (capecitabine + ludartin) treatment group was significantly lower than in the control, i.e., untreated group (p F6; 0.05). The combination treatment group also had significantly lower micro-vessel density in the tumor tissues, compared to the untreated control mice (p < 0.05).

Conclusion: These results show that a combination treatment of capecitabine and ludartin effectively inhibits colon tumor growth and angiogenesis in mice via a mechanism involving suppression of VEGF expression. Thus, capecitabine and ludartin combination is a potentially suitable treatment for colon cancer.

Keywords: Colon cancer, Mice, Ludartin, Leukopenia, VEGF expression, Angiogenesis